Empire Genomics Obtains CE Marking
Buffalo, NY December 17, 2015 – Empire Genomics has announced that it has received CE Mark designation for a number of its molecular diagnostic products. This is an important designation for the European Economic Area (EEA) and is a demonstration of the company’s commitment to providing the highest level of quality products.
"CE Marking of our products, such as we now have with our probes and the karyotyping media, will please our world distributors and will go a long way in accelerating sales in Europe,” says Dr Reza Mazaheri, Vice President of International Business Development for Empire Genomics.
Among the first to receive designation are a variety of cytogenetic media, immunohistochemistry products, and Fluorescence in Situ Hybridization (FISH) Probes. These products are all used in the cancer research and diagnosis market.
This designation demonstrates that Empire Genomics has met or exceeded all of the necessary standards, laws, and regulations of the European Commission (EC) and the European Union (EU).
About Empire Genomics, LLC
Empire Genomics, LLC is a global molecular diagnostics firm specializing in oncology products and clinical services. Technologies available include FISH, genotyping services, Next Generation Sequencing, as well as gene expression. The organization is a leader in the field of personalized medicine and helps clinicians, drug developers and researchers answer key questions in disease diagnosis, disease prognosis, and guiding ideal therapeutic interventions.
Media Contact:
Jessica Alexander
Marketing Operations
Phone: 716.856.3873
info@empiregenomics.com
"CE Marking of our products, such as we now have with our probes and the karyotyping media, will please our world distributors and will go a long way in accelerating sales in Europe,” says Dr Reza Mazaheri, Vice President of International Business Development for Empire Genomics.
Among the first to receive designation are a variety of cytogenetic media, immunohistochemistry products, and Fluorescence in Situ Hybridization (FISH) Probes. These products are all used in the cancer research and diagnosis market.
This designation demonstrates that Empire Genomics has met or exceeded all of the necessary standards, laws, and regulations of the European Commission (EC) and the European Union (EU).
About Empire Genomics, LLC
Empire Genomics, LLC is a global molecular diagnostics firm specializing in oncology products and clinical services. Technologies available include FISH, genotyping services, Next Generation Sequencing, as well as gene expression. The organization is a leader in the field of personalized medicine and helps clinicians, drug developers and researchers answer key questions in disease diagnosis, disease prognosis, and guiding ideal therapeutic interventions.
Media Contact:
Jessica Alexander
Marketing Operations
Phone: 716.856.3873
info@empiregenomics.com